Published in Nat Rev Microbiol on July 01, 2008
Oncolytic virotherapy. Nat Biotechnol (2012) 5.79
Adherens junction protein nectin-4 is the epithelial receptor for measles virus. Nature (2011) 2.94
Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev (2009) 2.28
Challenges with advanced therapy medicinal products and how to meet them. Nat Rev Drug Discov (2010) 2.09
Emerging biomedical applications of synthetic biology. Nat Rev Genet (2011) 2.05
New viruses for cancer therapy: meeting clinical needs. Nat Rev Microbiol (2013) 1.72
The heads of the measles virus attachment protein move to transmit the fusion-triggering signal. Nat Struct Mol Biol (2011) 1.61
The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers. Mol Ther (2011) 1.59
Tunable and reversible drug control of protein production via a self-excising degron. Nat Chem Biol (2015) 1.52
Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov (2015) 1.47
Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther (2010) 1.46
A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther (2011) 1.45
Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology (2013) 1.36
Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Cancer J (2012) 1.35
Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68. J Biomed Biotechnol (2010) 1.35
Targeting tumor vasculature with an oncolytic virus. Mol Ther (2011) 1.35
Conscripts of the infinite armada: systemic cancer therapy using nanomaterials. Nat Rev Clin Oncol (2010) 1.30
Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol (2012) 1.28
Engineered measles virus as a novel oncolytic therapy against prostate cancer. Prostate (2009) 1.25
Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res (2014) 1.23
Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents. Virology (2009) 1.23
Trial Watch:: Oncolytic viruses for cancer therapy. Oncoimmunology (2014) 1.22
Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J Clin Invest (2010) 1.22
Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther (2009) 1.21
"Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther (2009) 1.20
Mechanisms of protein kinase PKR-mediated amplification of beta interferon induction by C protein-deficient measles virus. J Virol (2010) 1.18
Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus. Mol Ther (2009) 1.15
The use of neural stem cells in cancer gene therapy: predicting the path to the clinic. Curr Opin Mol Ther (2010) 1.15
MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism. Mol Ther (2011) 1.15
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. Proc Natl Acad Sci U S A (2009) 1.14
Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor efficacy in immunocompetent and immunosuppressed Syrian hamsters. J Virol (2008) 1.14
An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector. Cancer Gene Ther (2009) 1.11
Gene therapy on the move. EMBO Mol Med (2013) 1.10
Cytokine determinants of viral tropism. Nat Rev Immunol (2009) 1.10
Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer. Cancer Res (2012) 1.10
Significant Growth Inhibition of Canine Mammary Carcinoma Xenografts following Treatment with Oncolytic Vaccinia Virus GLV-1h68. J Oncol (2010) 1.09
Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model. Cancer Gene Ther (2012) 1.08
Stress granule formation induced by measles virus is protein kinase PKR dependent and impaired by RNA adenosine deaminase ADAR1. J Virol (2012) 1.07
Adenosine deaminase acting on RNA 1 (ADAR1) suppresses the induction of interferon by measles virus. J Virol (2012) 1.02
Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Mol Ther (2012) 1.02
Oncolytic virotherapy in veterinary medicine: current status and future prospects for canine patients. J Transl Med (2012) 1.01
Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics. Gene Ther (2010) 0.99
Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model. Mol Ther (2009) 0.98
Infection and killing of multiple myeloma by adenoviruses. Hum Gene Ther (2010) 0.98
In situ adenovirus vaccination engages T effector cells against cancer. Vaccine (2009) 0.97
Artificial riboswitches for gene expression and replication control of DNA and RNA viruses. Proc Natl Acad Sci U S A (2014) 0.96
Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis. Mol Ther (2011) 0.96
Oncolysis by paramyxoviruses: preclinical and clinical studies. Mol Ther Oncolytics (2015) 0.95
New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster. Cancer Gene Ther (2009) 0.95
Paramyxovirus entry and targeted vectors for cancer therapy. PLoS Pathog (2010) 0.95
Oncolytic myxoma virus: the path to clinic. Vaccine (2013) 0.95
Oncolytic vesicular stomatitis virus induces apoptosis in U87 glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo. J Virol (2011) 0.95
Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide. Mol Ther (2010) 0.95
A recombinant measles virus unable to antagonize STAT1 function cannot control inflammation and is attenuated in rhesus monkeys. J Virol (2010) 0.94
Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency. Mol Ther Oncolytics (2015) 0.94
Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro. Leuk Res (2012) 0.94
Innate immune defense defines susceptibility of sarcoma cells to measles vaccine virus-based oncolysis. J Virol (2013) 0.93
Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma. Mol Ther (2012) 0.93
A novel armed oncolytic measles vaccine virus for the treatment of cholangiocarcinoma. Hum Gene Ther (2013) 0.93
Synthetic riboswitches for external regulation of genes transferred by replication-deficient and oncolytic adenoviruses. Nucleic Acids Res (2012) 0.93
Precise scheduling of chemotherapy primes VEGF-producing tumors for successful systemic oncolytic virotherapy. Mol Ther (2011) 0.92
Encapsulation of semiconducting polymers in vault protein cages. Nano Lett (2008) 0.90
Targeted entry of enveloped viruses: measles and herpes simplex virus I. Curr Opin Virol (2011) 0.90
Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors. J Virol (2012) 0.90
Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. PLoS Pathog (2013) 0.89
DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety. Mol Ther (2013) 0.88
The critical protein interactions and structures that elicit growth deregulation in cancer and viral replication. Wiley Interdiscip Rev Syst Biol Med (2010) 0.88
Oncolytic virotherapy for pancreatic cancer. Expert Rev Mol Med (2011) 0.88
Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus. Mol Ther (2014) 0.87
Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses. Mol Ther Methods Clin Dev (2016) 0.86
Species D adenoviruses as oncolytics against B-cell cancers. Clin Cancer Res (2011) 0.86
Enhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma. Mol Ther (2010) 0.85
Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade. Viruses (2016) 0.85
Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy. Oncolytic Virother (2015) 0.84
Directed evolution of a virus exclusively utilizing human epidermal growth factor receptor as the entry receptor. J Virol (2013) 0.84
Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases. Oncotarget (2015) 0.83
Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics. Virology (2015) 0.83
Novel viral vector systems for gene therapy. Viruses (2010) 0.83
EGFR-Targeted Adenovirus Dendrimer Coating for Improved Systemic Delivery of the Theranostic NIS Gene. Mol Ther Nucleic Acids (2013) 0.83
Measles virus entry through the signaling lymphocyte activation molecule governs efficacy of mantle cell lymphoma radiovirotherapy. Mol Ther (2013) 0.82
Proposed mechanisms of action for prostate cancer vaccines. Nat Rev Urol (2013) 0.82
Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic Viruses. Mol Ther (2015) 0.82
Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance. Nanomedicine (2015) 0.82
Oncolytic herpes simplex virus expressing yeast cytosine deaminase: relationship between viral replication, transgene expression, prodrug bioactivation. Cancer Gene Ther (2011) 0.82
The Engineering of a Novel Ligand in gH Confers to HSV an Expanded Tropism Independent of gD Activation by Its Receptors. PLoS Pathog (2015) 0.82
How to train your oncolytic virus: the immunological sequel. Mol Ther (2014) 0.81
Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy. J Virol (2013) 0.81
Morbillivirus infections: an introduction. Viruses (2015) 0.81
Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures. Gene Ther (2009) 0.81
CD20-targeted measles virus shows high oncolytic specificity in clinical samples from lymphoma patients independent of prior rituximab therapy. Gene Ther (2010) 0.81
Influence of method of systemic administration of adenovirus on virus-mediated toxicity: focus on mortality, virus distribution, and drug metabolism. J Pharmacol Toxicol Methods (2008) 0.81
Reporter gene imaging identifies intratumoral infection voids as a critical barrier to systemic oncolytic virus efficacy. Mol Ther Oncolytics (2014) 0.80
A fully replication-competent adenovirus vector with enhanced oncolytic properties. Cancer Gene Ther (2010) 0.80
Self-assembled lipid nanomedicines for siRNA tumor targeting. J Biomed Nanotechnol (2009) 0.80
TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer. Gene Ther (2010) 0.80
Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice. J Transl Med (2014) 0.80
Retargeting Strategies for Oncolytic Herpes Simplex Viruses. Viruses (2016) 0.80
Development of measles virus-based shielded oncolytic vectors: suitability of other paramyxovirus glycoproteins. Cancer Gene Ther (2013) 0.79
Oncolytic virus therapy for cancer. Oncolytic Virother (2013) 0.78
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
How cells respond to interferons. Annu Rev Biochem (1998) 24.27
STATs and gene regulation. Science (1997) 16.55
Antiviral actions of interferons. Clin Microbiol Rev (2001) 13.06
Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol (2008) 8.85
The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell (1993) 7.71
Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol (1993) 7.27
SLAM (CDw150) is a cellular receptor for measles virus. Nature (2000) 6.07
An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 5.97
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell (2003) 5.89
A road map for those who don't know JAK-STAT. Science (2002) 5.67
Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol (2001) 4.98
An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell (2001) 4.79
Host cell proteases controlling virus pathogenicity. Trends Microbiol (1994) 4.71
Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther (2000) 4.33
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med (2000) 4.15
The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci (2000) 3.91
Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol (2007) 3.86
Engineering targeted viral vectors for gene therapy. Nat Rev Genet (2007) 3.69
Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene (2005) 3.04
Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology (1987) 2.85
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene (2000) 2.81
mda-5, but not RIG-I, is a common target for paramyxovirus V proteins. Virology (2006) 2.64
Crystal structure of measles virus hemagglutinin provides insight into effective vaccines. Proc Natl Acad Sci U S A (2007) 2.56
STAT protein interference and suppression of cytokine signal transduction by measles virus V protein. J Virol (2003) 2.54
History of oncolytic viruses: genesis to genetic engineering. Mol Ther (2007) 2.51
Selectively receptor-blind measles viruses: Identification of residues necessary for SLAM- or CD46-induced fusion and their localization on a new hemagglutinin structural model. J Virol (2004) 2.42
Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat Med (1999) 2.42
Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci U S A (1999) 2.41
Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol (2005) 2.40
Paramyxovirus membrane fusion: lessons from the F and HN atomic structures. Virology (2006) 2.36
Mechanisms of inhibition of the host interferon alpha/beta-mediated antiviral responses by viruses. Microbes Infect (2002) 2.17
A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther (1998) 2.14
PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther (1999) 2.11
Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell (2004) 2.05
Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell (2005) 1.96
Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther (2007) 1.94
In vivo bioluminescence imaging for integrated studies of infection. Cell Microbiol (2004) 1.89
The hemagglutinin of canine distemper virus determines tropism and cytopathogenicity. J Virol (2001) 1.88
Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther (2005) 1.86
A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther (2003) 1.86
Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood (2001) 1.84
Tyrosine 110 in the measles virus phosphoprotein is required to block STAT1 phosphorylation. Virology (2006) 1.80
Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem (1997) 1.76
Weapons of STAT destruction. Interferon evasion by paramyxovirus V protein. Eur J Biochem (2004) 1.74
Measles virus V protein blocks interferon (IFN)-alpha/beta but not IFN-gamma signaling by inhibiting STAT1 and STAT2 phosphorylation. FEBS Lett (2003) 1.74
Transcriptional activation of alpha/beta interferon genes: interference by nonsegmented negative-strand RNA viruses. J Virol (2005) 1.64
An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. Cancer Res (2005) 1.63
Dissection of measles virus V protein in relation to its ability to block alpha/beta interferon signal transduction. J Gen Virol (2004) 1.59
"Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol (2001) 1.53
Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res (2007) 1.50
Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol (2003) 1.48
Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: an opposite effect of chemotherapy. Cancer Res (2008) 1.46
Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol (2000) 1.44
p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J Virol (1998) 1.44
Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer (1957) 1.43
Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J Virol (2000) 1.43
Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther (2001) 1.42
Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res (2007) 1.41
Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Ther (1999) 1.37
Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol Ther (2006) 1.32
Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J Virol (2001) 1.31
Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood (1998) 1.28
Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood (2002) 1.27
Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells. J Virol (2006) 1.25
A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Ther (2004) 1.23
Engineering oncolytic measles virus to circumvent the intracellular innate immune response. Mol Ther (2007) 1.23
Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor. Proc Natl Acad Sci U S A (2006) 1.22
Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus. Cancer (1952) 1.21
An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol Ther (2007) 1.21
B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells. J Virol (1999) 1.18
Genetically targeted adenovirus vector directed to CD40-expressing cells. J Virol (2003) 1.18
Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Ther (2008) 1.18
Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus. Mol Ther (2006) 1.16
Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res (1994) 1.15
An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nat Biotechnol (1998) 1.14
Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol Ther (2005) 1.13
Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res (2006) 1.12
Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia. Hum Gene Ther (2007) 1.08
An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol Ther (2003) 1.07
Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model. Cancer Gene Ther (2006) 1.07
Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. Mol Ther (2003) 1.04
Induced apoptosis supports spread of adenovirus vectors in tumors. Hum Gene Ther (2001) 1.03
The oncolytic virotherapy treatment platform for cancer: unique biological and biosafety points to consider. Cancer Gene Ther (2002) 1.03
E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects. Hum Gene Ther (2007) 1.02
Molecular imaging of host-pathogen interactions in intact small animals. Cell Microbiol (2004) 1.01
An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery. Gene Ther (2006) 1.00
Nitroreductase: a prodrug-activating enzyme for cancer gene therapy. Clin Exp Pharmacol Physiol (2004) 0.99
Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL. Cancer Gene Ther (2007) 0.99
Inhibition of transplantable and spontaneous murine tumours by the M-P virus. Nature (1965) 0.98
Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner. Hum Gene Ther (2003) 0.98
Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression. Gene Ther (2005) 0.98
Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus. Clin Cancer Res (2006) 0.97
Viruses with oncolytic properties and their adaptation to tumors. Ann N Y Acad Sci (1952) 0.95
Generation of a recombinant Sendai virus that is selectively activated and lyses human tumor cells expressing matrix metalloproteinases. Gene Ther (2004) 0.93
New developments in the virus therapy of cancer: a historical review. Intervirology (1993) 0.93
Impaired alpha-interferon signaling in transitional cell carcinoma: lack of p48 expression in 5637 cells. Cancer Res (2001) 0.90
Modification of the p53 transgene of a replication-competent adenovirus prevents mdm2- and E1b-55kD-mediated degradation of p53. Cancer Gene Ther (2006) 0.90
ONCOLYTIC EFFECT OF POLIOMYELITIS VIRUS ON HUMAN EPIDERMOID CARCINOMA (HELA TUMOR) HETEROLOGOUSLY TRANSPLANTED TO GUINEA PIGS. Am J Pathol (1964) 0.89
Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer. J Biomed Opt (2007) 3.04
Measles virus blind to its epithelial cell receptor remains virulent in rhesus monkeys but cannot cross the airway epithelium and is not shed. J Clin Invest (2008) 2.21
Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther (2007) 1.94
Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther (2005) 1.86
Protection of the coronary arteries during epicardial radiofrequency ablation with intracoronary chilled saline irrigation: assessment in an in vitro model. J Cardiovasc Electrophysiol (2006) 1.70
Characterization of species C human adenovirus serotype 6 (Ad6). Virology (2011) 1.59
Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus. Cancer Res (2008) 1.57
Lentiviral vectors: basic to translational. Biochem J (2012) 1.49
Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther (2011) 1.42
Preparation and titration of CsCl-banded adenovirus stocks. Methods Mol Med (2007) 1.36
Metabolically biotinylated adenovirus for cell targeting, ligand screening, and vector purification. Mol Ther (2003) 1.33
Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol Ther (2008) 1.28
Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines. PLoS One (2009) 1.26
Avidin-based targeting and purification of a protein IX-modified, metabolically biotinylated adenoviral vector. Mol Ther (2004) 1.26
Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents. Virology (2009) 1.23
Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus. Hum Gene Ther (2009) 1.21
Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo. J Virol (2009) 1.18
Expanded anticancer therapeutic window of hexon-modified oncolytic adenovirus. Mol Ther (2009) 1.15
Bipolar ablation of the interventricular septum is more efficient at creating a transmural line than sequential unipolar ablation. Pacing Clin Electrophysiol (2010) 1.15
Rapid construction of capsid-modified adenoviral vectors through bacteriophage lambda Red recombination. Hum Gene Ther (2004) 1.15
MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism. Mol Ther (2011) 1.15
Early events in retrovirus XMRV infection of the wild-derived mouse Mus pahari. J Virol (2010) 1.13
Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting. Virology (2006) 1.11
Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors. J Virol (2011) 1.09
Cryoelectron microscopy of protein IX-modified adenoviruses suggests a new position for the C terminus of protein IX. J Virol (2006) 1.09
Polyethylene glycol modification of adenovirus reduces platelet activation, endothelial cell activation, and thrombocytopenia. Hum Gene Ther (2007) 1.08
Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine (2007) 1.08
A chimeric adenovirus vector encoding reovirus attachment protein sigma1 targets cells expressing junctional adhesion molecule 1. Proc Natl Acad Sci U S A (2004) 1.08
Effects of shielding adenoviral vectors with polyethylene glycol on vector-specific and vaccine-mediated immune responses. Hum Gene Ther (2008) 1.01
Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines. Viruses (2009) 1.01
In vivo evaluation of gene therapy vectors in ex vivo-derived marrow stromal cells for bone regeneration in a rat critical-size calvarial defect model. Hum Gene Ther (2003) 1.01
Infection and killing of multiple myeloma by adenoviruses. Hum Gene Ther (2010) 0.98
In vitro release of plasmid DNA from oligo(poly(ethylene glycol) fumarate) hydrogels. J Control Release (2005) 0.97
The role of T cell antagonism and original antigenic sin in genetic immunization. J Immunol (2002) 0.96
Systemic delivery of therapeutic viruses. Curr Opin Mol Ther (2009) 0.96
Evaluation of bone regeneration by DNA release from composites of oligo(poly(ethylene glycol) fumarate) and cationized gelatin microspheres in a critical-sized calvarial defect. J Biomed Mater Res A (2006) 0.95
Generation of a Kupffer cell-evading adenovirus for systemic and liver-directed gene transfer. Mol Ther (2011) 0.95
Characterization of DNA release from composites of oligo(poly(ethylene glycol) fumarate) and cationized gelatin microspheres in vitro. J Biomed Mater Res A (2006) 0.95
Targeting adenoviruses with factor x-single-chain antibody fusion proteins. Hum Gene Ther (2010) 0.95
Adeno-associated virus serotype 8 gene transfer rescues a neonatal lethal murine model of propionic acidemia. Hum Gene Ther (2011) 0.93
Synthesis and conformational evaluation of a novel gene delivery vector for human mesenchymal stem cells. Biomacromolecules (2008) 0.92
Deoxyribonuclease II is a lysosomal barrier to transfection. Mol Ther (2003) 0.91
Global gene expression profiling of pancreatic islets in mice during streptozotocin-induced β-cell damage and pancreatic Glp-1 gene therapy. Dis Model Mech (2013) 0.91
A library-selected, Langerhans cell-targeting peptide enhances an immune response. DNA Cell Biol (2004) 0.90
Maximizing antigen targeting to the proteasome for gene-based vaccines. Mol Ther (2004) 0.90
Circulating antibodies and macrophages as modulators of adenovirus pharmacology. J Virol (2013) 0.90
Selection of muscle-binding peptides from context-specific peptide-presenting phage libraries for adenoviral vector targeting. J Virol (2005) 0.89
Short-term rescue of neonatal lethality in a mouse model of propionic acidemia by gene therapy. Hum Gene Ther (2009) 0.88
Intramyocardial adiposity after myocardial infarction: new implications of a substrate for ventricular tachycardia. Circulation (2013) 0.88
Comparison of electroanatomic contact and noncontact mapping of ventricular scar in a postinfarct ovine model with intramural needle electrode recording and histological validation. Circ Arrhythm Electrophysiol (2008) 0.87
Protection against divergent influenza H1N1 virus by a centralized influenza hemagglutinin. PLoS One (2011) 0.87
Species D adenoviruses as oncolytics against B-cell cancers. Clin Cancer Res (2011) 0.86
Selection of chronic lymphocytic leukemia binding peptides. Cancer Res (2003) 0.85
Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV. PLoS One (2013) 0.83
Heme oxygenase-1 regulates the immune response to influenza virus infection and vaccination in aged mice. FASEB J (2012) 0.83
Development and characterization of enhanced green fluorescent protein and luciferase expressing cell line for non-destructive evaluation of tissue engineering constructs. Biomaterials (2004) 0.83
Generation of a hypomorphic model of propionic acidemia amenable to gene therapy testing. Mol Ther (2013) 0.82
Low seroprevalent species D adenovirus vectors as influenza vaccines. PLoS One (2013) 0.81
Increased transduction of skeletal muscle cells by fibroblast growth factor-modified adenoviral vectors. Hum Gene Ther (2006) 0.81
Real-time dynamic imaging of virus distribution in vivo. PLoS One (2011) 0.81
A vector-host system to fingerprint virus tropism. Hum Gene Ther (2012) 0.81
Repertoire and immunofocusing of CD8 T cell responses generated by HIV-1 gag-pol and expression library immunization vaccines. J Immunol (2004) 0.80
Generation of genome-wide CD8 T cell responses in HLA-A*0201 transgenic mice by an HIV-1 ubiquitin expression library immunization vaccine. J Immunol (2002) 0.80
Improved transduction of human corneal epithelial progenitor cells with cell-targeting adenoviral vectors. Exp Eye Res (2006) 0.79
Clinical evaluation of a new technique to monitor return electrode skin temperature during radiofrequency ablation. J Interv Card Electrophysiol (2012) 0.79
Rad23 as a reciprocal agent for stimulating or repressing immune responses. Hum Gene Ther (2005) 0.78
Beta cell regeneration after single-round immunological destruction in a mouse model. Diabetologia (2014) 0.78
Early osteoblastic differentiation induced by dexamethasone enhances adenoviral gene delivery to marrow stromal cells. J Orthop Res (2004) 0.77
CD46-mediated transduction of a species D adenovirus vaccine improves mucosal vaccine efficacy. Hum Gene Ther (2014) 0.77
Effects of adeno-associated virus serotype and tissue-specific expression on circulating biomarkers of propionic acidemia. Hum Gene Ther (2014) 0.77
Activation of refractory T cell responses against hepatitis C virus core protein by ablation of interfering hydrophobic domains. Mol Ther (2005) 0.77
Long-term sex-biased correction of circulating propionic acidemia disease markers by adeno-associated virus vectors. Hum Gene Ther (2015) 0.77
Comparison of adenoviruses as oncolytics and cancer vaccines in an immunocompetent B cell lymphoma model. Hum Gene Ther (2011) 0.76
Electrical impedance tomography for assessing ventilation/perfusion mismatch for pulmonary embolism detection without interruptions in respiration. Conf Proc IEEE Eng Med Biol Soc (2014) 0.75
Targeted delivery of expression plasmids to the lung via macroaggregated polyethylenimine-albumin conjugates. Methods Mol Med (2003) 0.75
Percutaneous microwave ablation with a long side-firing antenna array can successfully treat a nonsurgical chronic ovine atrial flutter model. J Cardiovasc Electrophysiol (2009) 0.75
Common cold, uncommon variation. N Engl J Med (2009) 0.75
Simultaneous biventricular noncontact mapping and ablation of septal ventricular tachycardia in a chronic ovine infarct model. Circ Arrhythm Electrophysiol (2009) 0.75
Revised non-contact mapping of ventricular scar in a post-infarct ovine model with validation using contact mapping and histology. Europace (2010) 0.75
Generation of multivalent genome-wide T cell responses in HLA-A*0201 transgenic mice by an HIV-1 expression library immunization (ELI) vaccine. Res Initiat Treat Action (2003) 0.75
Advancing aspirin utilization: a review of clinical and systems-based interventions. Am J Med Qual (2010) 0.75
Transcatheter non-contact microwave ablation may enable circumferential renal artery denervation while sparing the vessel intima and media. EuroIntervention (2016) 0.75
Bone regeneration through transplantation of genetically modified cells. Clin Plast Surg (2003) 0.75
Evaluation of noncontact mapping by comparison with simultaneous multisite contact recordings in acute ischemic ventricular fibrillation. J Cardiovasc Electrophysiol (2010) 0.75